|
Market Closed -
Nasdaq
08:16:00 30/10/26 am AEDT
|
5-day change
|
1st Jan Change
|
|
7,318.44 PTS
|
+0.86%
|
|
+1.84%
|
+27.14%
|
| Current month | +2.87% | | | | 1 month | +2.60% | | |
|
30/10 |
Gilead hikes 2026 sales outlook, says Medicare cuts Biktarvy price by 38% starting in 2028
|
RE
| |
30/10 |
Earnings Flash (STOK) Stoke Therapeutics Posts Q3 Loss $1.08, vs. FactSet Est of $0.93 Loss
|
MT
| |
30/10 |
Earnings Flash (SUPN) Supernus Pharmaceuticals Posts Q3 EPS $0.35, vs. FactSet Est of $0.08 Loss
|
MT
| |
30/10 |
BridgeBio Pharma Q3 Net Loss Narrows, Revenue Rises
|
MT
| |
30/10 |
Illumina Q3 Adjusted Earnings, Revenue Rise
|
MT
| |
30/10 |
PTC Therapeutics Swings to Q3 Loss, Revenue Rises; Increases 2026 Outlook
|
MT
| |
30/10 |
Exelixis Q3 Adjusted Earnings, Revenue Rise
|
MT
| |
30/10 |
Earnings Flash (BBIO) BridgeBio Pharma Posts Q3 Per-Share Loss $0.42, vs. FactSet Est of $0.54 Loss
|
MT
| |
30/10 |
(ILMN) Illumina Expects Fiscal 2026 Adjusted EPS Range $5.40-$5.45, vs. FactSet Est of $5.35
|
MT
| |
30/10 |
(PTCT) PTC Therapeutics Expects Full Year 2026 Revenue Range $1.29B - $1.32B, vs. FactSet Est of $1.26B
|
MT
|
No results match your criteria
| Date |
Price |
Change |
|
29/10/26
|
PTS 7,318.44 |
+0.86%
|
|
28/10/26
|
PTS 7,256.33 |
+1.48%
|
|
27/10/26
|
PTS 7,150.77 |
+1.87%
|
|
26/10/26
|
PTS 7,019.19 |
+0.38%
|
|
23/10/26
|
PTS 6,992.35 |
-1.13%
|
Highest NASDAQ Biotechnology increases
|
|
|
|
+9.73%
|
|
|
+9.21%
|
|
|
+9.00%
|
|
|
+8.72%
|
|
|
+8.28%
|
|
|
+0.44%
|
The sharpest declines in NASDAQ Biotechnology.
|
|
|
|
-9.07%
|
|
|
-9.09%
|
|
|
-10.61%
|
|
|
-22.55%
|
| 1 week | +3.48% | | | | Current month | +2.87% | | | | 1 month | +2.60% | | | | 3 months | +12.22% | | | | 6 months | +27.19% | | | | Current year | +28.23% | | |
Select your edition All financial news and data tailored to specific country editions |